- Home
- MNOV vs VTGN Comparison
MNOV vs VTGN Comparison
Compare MNOV & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | VTGN |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 21.8M |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MNOV | VTGN |
|---|---|---|
| Price | $1.44 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $7.50 | $0.90 |
| AVG Volume (30 Days) | 55.9K | ★ 417.5K |
| Earning Date | 05-12-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,360,807.00 | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.13 | $0.43 |
| 52 Week High | $1.96 | $5.14 |
Technical Indicators
Market Signals| Indicator | MNOV | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 45.48 |
| Support Level | $1.40 | $0.57 |
| Resistance Level | $1.60 | $0.60 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 38.68 | 35.85 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.